证券代码：300171 证券简称：东富龙 东富龙科技集团股份有限公司投资者关系活动记录表 编号：2023-002 您好，感谢您的关注。目前公司协调一切资源来推进在手订 单的制造和交付，谢谢。 6、公司 2022 年核销了 2200 万应收账款，有大量知名上市 公司（康泰、金赛、辅仁、通化东宝）也在其中，请问这些费用 具体是什么？公司有严格的内控制度为何有大量对方明明有支 付力但是却回收的费用？ 您好，2200 万应收账款为按照单项计提的期末余额，不是 核销，详细情况请参见公司年报。公司对公司的资产质量一直很 关注，在会计准则的框架要求下，采用了行业里较高的测试标准， 来保证资产质量的真实性和可变现性。谢谢。 7、董事长好，我想问问根据 2022 年公司关于医疗装备及耗 材这一块的收入是 3.597 亿元，相比较 2021 年公司关于医疗装 备与耗材这一块的收入是 4.995 亿元，请问一下为什么这一块公 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 ■业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 参与 ...

Financial Performance - The company achieved a total operating revenue of 5.469 billion yuan, representing a year-on-year growth of 30.46%[28] - The net profit attributable to shareholders was 847 million yuan, an increase of 2.27% compared to the previous year[28] - The company's total operating revenue for the year was approximately ¥5.47 billion, with a year-on-year increase of 30.50%[32] - The total operating revenue for 2022 reached ¥5,469,426,362.12, representing a year-on-year increase of 30.46% compared to ¥4,192,421,107.34 in 2021[60] - The net profit for 2022 reached CNY 903,039,034.78, up from CNY 886,168,898.32 in the previous year, representing a growth of 1.0%[126] - The basic earnings per share for 2022 was CNY 1.34, compared to CNY 1.32 in 2021, indicating a slight increase of 1.5%[126] - The total profit for 2022 was CNY 1,002,413,371.46, a decrease of 1.0% from CNY 1,019,562,424.48 in 2021[126] - The company's financial expenses for 2022 showed a significant improvement, with a net financial income of CNY -36,652,671.22 compared to CNY -4,364,888.27 in 2021[131] Revenue Breakdown - International revenue accounted for approximately 19.18% of total revenue, which was below expectations and impacted overall gross margin levels[28] - The revenue from injection machines and systems reached approximately ¥2.27 billion, with a gross profit margin of 43.22%[32] - The revenue from the Asia region was approximately ¥650.56 million, reflecting a year-on-year increase of 118.31%[32] - The company experienced a significant increase in revenue from the African market, with a year-on-year growth of 1,101.55%[32] - The revenue from South America increased by 129.32%, reaching ¥1,944,916.17, compared to ¥848,117.29 in 2021[61] - The biopharmaceutical engineering machines and systems generated ¥1,123,071,799.76, which is 20.53% of total revenue, reflecting a year-on-year increase of 23.85%[60] - The revenue from injection machines and systems was ¥2,268,041,740.72, accounting for 41.47% of total revenue, with a significant growth of 64.19% from ¥1,381,367,353.04 in 2021[60] Research and Development - The company is focusing on innovation and upgrading in the pharmaceutical equipment industry, transitioning from imitation to independent research and development[21] - The company is enhancing its research and development capabilities and expanding its product offerings to meet diverse customer needs in the pharmaceutical sector[28] - The company has made significant advancements in R&D and technology transfer, holding core technologies in the pharmaceutical equipment industry[54] - The company's R&D investment for the past three years has been consistently zero, indicating no capitalized R&D expenses[73] - R&D expenses increased by 332,848,006.52, up 16.99%, driven by enhanced R&D investment, multiple project implementations, and an increase in high-tech talent[94] - The company completed several R&D projects, including a high-temperature sterilization machine with a heat recovery rate of over 90%[1] - The company achieved a net profit increase driven by the successful development of domestic production materials for biopharmaceuticals, including disposable bioreactor bags and stirring bags, which align with market trends for domestic substitution of imported products[1] Market Expansion and Strategy - The company has established sales and technical service networks both domestically and internationally to enhance market expansion[25] - The company is committed to a development strategy centered on systematization, internationalization, and digitalization[28] - The company plans to continue expanding its market presence and investing in new technologies and products, as indicated by the significant capital expenditures listed in the funding allocation[116] - The company aims to enhance its international market share while consolidating its domestic brand position[157] - The company plans to actively pursue mergers and acquisitions to accelerate growth in the life sciences and food equipment sectors[159] - The company is actively pursuing mergers and acquisitions to seek new growth points, despite potential risks associated with external acquisitions[176] Financial Position and Cash Flow - As of the end of 2022, cash and cash equivalents amounted to ¥4,710,070,214.21, representing 35.21% of total assets, an increase of 10.04% from the beginning of the year[78] - The company reported a significant increase in cash flow from financing activities, with a net cash flow of 2,428.31 million yuan, reflecting a 1102.78% increase compared to the previous year due to new share issuance[102] - The cash flow from operating activities was negative at approximately -¥166.69 million in Q1 2022, but turned positive in subsequent quarters[43] - The company’s cash flow from operating activities showed discrepancies due to increased receivables and higher inventory purchases, indicating a need for better cash management[103] - The cash inflow from operating activities was approximately ¥5.48 billion, a decrease of 8.1% from ¥5.97 billion in 2021[135] - The cash outflow from operating activities increased to approximately ¥5.24 billion in 2022, up 14% from ¥4.60 billion in 2021[135] Corporate Governance and Management - The company has established a governance structure that complies with the requirements set by the China Securities Regulatory Commission[200] - The company emphasizes integrity and compliance in its operations, aiming to enhance corporate governance and internal control systems[200] - The company has established a performance evaluation system for its board members and senior management to ensure transparency and compliance[182] - The company underwent a board restructuring on February 3, 2023, with several key personnel changes, including the election of new directors and supervisors[190] - The restructuring includes the appointment of a new financial director, Gao Zhijian, to strengthen financial management[190] - The company is committed to improving management efficiency and addressing operational challenges through enhanced management systems and platforms[160] Challenges and Risks - The company's international market share remains low due to challenges in funding scale, capacity construction, and process technology compared to leading foreign enterprises[56] - The pharmaceutical industry is undergoing rapid transformation, increasing competition and potential risks to the company's main business profitability[172] - The company acknowledges the risks posed by significant currency fluctuations due to its increasing export business[176]

Financial Performance - The total operating revenue for Q1 2023 was CNY 1,422,858,225.87, an increase of 14.87% compared to CNY 1,237,346,728.25 in Q1 2022[16] - The total operating costs for Q1 2023 were CNY 1,135,707,952.42, up 15.83% from CNY 980,425,006.32 in the same period last year[16] - The company's net profit for the current period is 243,338,626.35, an increase from 221,320,818.08 in the previous period, representing a growth of approximately 9.14%[18] - The total operating profit is reported at 274,411,481.41, compared to 252,461,174.32 in the previous period, indicating an increase of about 8.25%[18] - The total comprehensive income attributable to the parent company is 230,857,206.65, up from 211,450,946.94, reflecting a growth of approximately 9.73%[19] - Net profit attributable to shareholders was ¥231,048,479.97, up 9.26% from ¥211,462,634.61 year-over-year[35] - The net profit after deducting non-recurring gains and losses was ¥225,197,150.32, reflecting a 13.85% increase from ¥197,798,763.79 in the previous year[35] Cash Flow - The net cash flow from operating activities increased by 94.43% year-on-year, primarily due to a decrease in cash paid for purchasing goods[9] - The company reported a net cash outflow from operating activities of -9,291,858.17, an improvement from -166,688,330.83 in the previous period[31] - The cash inflow from operating activities totaled CNY 1,273,537,066.45, an increase of 2.4% compared to CNY 1,240,437,375.08 in the previous period[64] - The cash received from sales of goods and services was CNY 1,068,134,345.88, down 8.9% from CNY 1,172,484,201.60 in the prior period[64] - The cash paid for purchasing goods and services decreased by 26.2% to CNY 700,580,832.04 from CNY 949,822,649.50 in the previous period[64] - The cash received from tax refunds increased to CNY 7,445,654.79, up 39.4% from CNY 5,337,054.53 in the prior period[64] - The cash and cash equivalents at the end of the period stand at 3,862,207,001.03, compared to 2,397,657,876.66 at the end of the previous period, indicating an increase of approximately 61.19%[31] Assets and Liabilities - The company's total assets as of the end of Q1 2023 were CNY 13,264,581,712.38, a slight decrease from CNY 13,376,964,068.56 at the end of the previous year[16] - The total liabilities decreased to CNY 5,362,842,947.98 from CNY 5,732,944,396.41 in the previous year[16] - The company's cash and cash equivalents were CNY 3,865,472,995.94, down from CNY 4,710,070,214.21 in the previous year[14] - Inventory as of Q1 2023 was CNY 3,896,371,672.45, slightly down from CNY 3,899,309,956.37 in the previous year[15] - The company reported a significant increase in contract assets, which rose by 22.83% to CNY 394,737,047.69 from CNY 321,369,147.43 year-on-year[15] - The company's equity attributable to shareholders increased to CNY 7,685,291,362.16 from CNY 7,442,561,668.87 in the previous year[16] - Total assets at the end of the reporting period were ¥13,264,581,712.38, a decrease of 0.84% from ¥13,376,964,068.56 at the end of the previous year[36] - Shareholders' equity attributable to the parent company increased by 3.26% to ¥7,685,291,362.16 from ¥7,442,561,668.87 year-over-year[36] Investments and Financing - The company experienced a significant increase in financing cash flow, with a net increase of 398.36% compared to the previous year, primarily due to new investments from minority shareholders[23] - The company recorded an investment cash outflow of 953,986,240.85, a decrease from 1,041,982,673.15 in the previous period[31] - Financial expenses increased by 901.15% year-over-year, primarily due to an increase in interest income[39] - Investment income decreased by 96.44% compared to the previous year, mainly due to losses from associated companies[39] - The company reported a significant increase of 266.08% in trading financial assets, attributed to increased purchases of bank wealth management products[48] Shareholder Information - The total number of shareholders is 10, with the largest shareholder, Zheng Xiaodong, holding 34.31% of the shares[68] - The company plans to issue shares to specific investors, as approved by the Shenzhen Stock Exchange on July 13, 2022[72] Employee Compensation - The number of employees' performance bonuses paid in the current period led to a 39.28% decrease in payable employee compensation compared to the beginning of the period[67]

证券代码：300171 证券简称：东富龙 公告编号：2023-030 欢迎广大投资者积极参与本次网上业绩说明会。 特此公告。 东富龙科技集团股份有限公司 东富龙科技集团股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 东富龙科技集团股份有限公司（以下简称"公司"）《2022 年年度报告》全文 及摘要已于 2023 年 4 月 27 日披露于巨潮资讯网（http://www.cninfo.com.cn），为 了让广大投资者能进一步了解公司《2022 年年度报告》及经营情况，公司将于 2023 年 5 月 12 日（星期五）下午 15:00-17:00 在全景网举行 2022 年度网上业绩 说明会。本次年度业绩说明会采用网络远程的方式举行，投资者可登录"全景·路 演天下"（http://rs.p5w.net）参与互动交流。 出席本次年度业绩说明会的人员有：董事长兼总经理郑效东先生、财务总监 郜志坚先生、副总经理兼董事会秘书王艳女士、独立董事张爱民先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 ...

Group 1: Company Overview and Strategic Goals - Dongfulong is a leading enterprise in pharmaceutical equipment in China, focusing on systematic and international development strategies [4] - The company aims for an annual revenue growth of 20%, targeting a total sales revenue of 5 billion CNY by 2020, with specific revenue goals of 3.5 billion CNY from pharmaceutical equipment, 1 billion CNY from medical equipment, and 500 million CNY from food equipment [4] Group 2: Market Position and Collaborations - Dongfulong collaborates with several world-renowned pharmaceutical companies, including Amgen, GSK, and Boehringer Ingelheim, to sell freeze-drying equipment and production lines [4] - In India, the company has sold over 200 freeze-drying machines, establishing a brand presence and transitioning from single machines to complete sterile isolation freeze-drying production lines [4] Group 3: Industrial 4.0 Implementation - The company is advancing towards higher GMP standards and increased automation and intelligence in pharmaceutical equipment, driven by the "Made in China 2025" strategy [5] - Dongfulong's smart control products focus on both product development and market expansion, with an average renovation cost of 6 million CNY for existing pharmaceutical factories [6] Group 4: Smart Factory Development - The market potential for renovating existing workshops is estimated at 60-100 billion CNY, assuming 50% of the 4,000 pharmaceutical factories in China require upgrades [6] - The four core components of a smart factory include integration, intelligent devices, connectivity, and big data [7] Group 5: Precision Medicine Initiatives - In 2015, Dongfulong laid the foundation for its precision medicine core business, planning to establish five medical centers across major cities in China by 2016 [9] - The company aims to integrate various diagnostic technology platforms and personalized diagnostic products, seeking overseas collaborations for rapid product registration [9][10]

证券代码：300171 证券简称：东富龙 编号：2016-001 上海东富龙科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------|----------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 交银施罗德：楼慧源、于渤、杨浩、沈楠、邱华； | | 人员姓名 | 中海基金：胡攸乔； | | | | 华安基金：袁银泉； | | | | 长信基金：陈益凌； | | | | 太平洋资管：杜永宏； | | | | 齐鲁证券资管：张素豪； | | | | 华泰证券资管：冯皓琪； | | | | 银河证券：焦德智； | | | | 兴业证券：徐佳熹； | | | | 海通证券：周锐； | | | -- ...

证券代码：300171 证券简称：东富龙 上海东富龙科技股份有限公司投资者关系活动记录表 编号：2020-001 | --- | --- | --- | |------------------|---------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | □ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □ 新闻发布会 □路演活动 | | | | □ | 现场参观 ■其他 （电话会议） | | ...

证券代码：300171 证券简称：东富龙 上海东富龙科技股份有限公司投资者关系活动记录表 编号：2020-002 | --- | --- | --- | |----------------|----------------------------|------------------------------------------| | | ■ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ 媒体采访 □业绩说明会 | | | 类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 □其他 | | | | 东方证券：张智尧 | | | 参与单位名称 | | 道余资本：陈道余、林伟鑫、史红伟、姚来岑 | | 及人员姓名 | 玺顺投资：王兆红 | | | | 中国平安：李浩 | | | 时间 | 2020 年 6 月 2 | 日 15： 00-16：30 | | 地点 | 上海市闵行区都会路 | 139 号五楼会议室 | | 上市公司接待 | 董事：唐惠兴 | | | 人员姓名 | 副总经理：程锦生 | | | | 副总经理兼董事会秘书：王艳 | | | --- | --- | |-- ...

证券代码：300171 证券简称：东富龙 上海东富龙科技股份有限公司投资者关系活动记录表 编号：2020-003 | --- | --- | --- | |------------------|--------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | ■ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □ | 新闻发布会 □路演活动 | | | □ 现场参观 □其他 | | | 参与单位名称 | | 国信证券：谢长雁、陈曦炳 ...